10 Pharmaceutical Stocks to Buy Today According to Tiger Cub Billionaire Lee Ainslie insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.
Wave Life Sciences Ltd (NASDAQ: WVE) has announced the first proof-of-concept preclinical data for its ADAR (adenosine deaminases acting on RNA)-mediated RNA editing program in alpha-1 antitrypsin deficiency (AATD).
AATD is a genetic disorder that may result in lung disease or liver. Read More. Don t Miss Any Updates! News Directly in Your Inbox Subscribe to:
Wave Life Sciences to Present at Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to give a presentation at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 11:30 a.m. ET. Dr. Bolno will provide a corporate update and discuss Wave’s pipeline programs, including the first
in vivo data from the company’s ADAR editing discovery program for alpha-1 antitrypsin deficiency (AATD).
A live webcast of the presentation will be available on the investor relations page of the Wave Life Sciences corporate website at http://ir.wavelifesciences.com. A replay of the presentation will be archived and available at that site for 90 days following the event.